Researchers at King’s College London have identified a promising new therapeutic strategy for Alzheimer’s disease by targeting several of the…
Read More
Bioengineered Bone Marrow-on-a-Chip Platform Revolutionizes Human Hematopoiesis Research and Drug Toxicity Screening
The human bone marrow is a complex, sequestered organ that serves as the primary engine for the body’s circulatory and…
Read More
Existing Chronic Constipation Drug Shows Potential in Treating Cognitive Impairment and Brain Fog Associated with Depression
The medical community has long recognized that the journey to recovery from major depressive disorder (MDD) is rarely a linear…
Read More
Affinia Therapeutics Secures FDA Orphan Drug Designation for AFTX-201, a Promising Gene Therapy for BAG3-Associated Dilated Cardiomyopathy
Affinia Therapeutics has announced a significant milestone in the development of its investigational gene therapy, AFTX-201, with the US Food…
Read More
How most-favored-nation pricing is reshaping generic drug economics, according to Dr. Reddy’s finance director
The landscape of generic drug economics in the United States is undergoing a significant transformation, largely driven by the advent…
Read More
Verseon bets physics can take drug design beyond AI’s training data
Bay Area-based pharmaceutical company Verseon has been a quiet pioneer in computational drug design since 2002, predating the widespread emergence…
Read More
Shape-Shifting Drug Design Supercharges Cancer Medication by Attacking Tumors on Multiple Fronts
A groundbreaking advancement in cancer therapeutics has emerged from Washington University School of Medicine in St. Louis, where researchers have…
Read More
Bioengineered Bone Marrow-on-a-Chip Platform Replicates Human Immune Response and Advances Drug Development Capabilities
The human skeletal system serves as more than just a structural framework; deep within the cavities of our bones lies…
Read More
Pens to Pills: The Transformative Era of Oral GLP-1 Receptor Agonists in Drug Discovery and Patient Care
The pharmaceutical landscape for metabolic diseases has reached a pivotal inflection point, marked by the recent approval of the first…
Read More
How most-favored-nation pricing is reshaping generic drug economics, according to Dr. Reddy’s finance director
The United States, long an outlier in global pharmaceutical pricing, is undergoing a profound transformation in its drug cost landscape,…
Read MoreYOU MAY HAVE MISSED
